Summary
Other Scenarios:
- GSK - NVS
- GSK - MRK
- NVS - TEVA
- MRK - TEVA
| Buyer: | GlaxoSmithKline PLC (GSK) | Last Price: | 44.18 | Market Cap.: | 112.21B |
|---|---|---|---|---|---|
| Target: | Teva Pharmaceutical Industries Ltd (TEVA) | Last Price: | 38.90 | Market Cap.: | 36.58B |
Lines of Business Summary:
- GlaxoSmithKline PLC (GSK) competes in 2 industries and 248 product/service groups
- Teva Pharmaceutical Industries Ltd (TEVA) competes in 1 industry and 506 product/service groups
- A combined entity will have 14% Product/Service Group overlap
- GlaxoSmithKline PLC (GSK) has 12 and Teva Pharmaceutical Industries Ltd (TEVA) has 1 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Consumer |
|
890 | |
Consumer Products and Services |
|
341 | |
|
Healthcare |
|
|
732 |
|
Biopharmaceuticals |
|
|
334 |
|
Medical Devices |
|
|
177 |
|
Nutritional Health |
|
26 | |
|
Outsourced Biomedical Services |
|
|
39 |
|
Scientific Products |
|
23 | |
|
Veterinary Products and Services |
|
8 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 334)
|
Target (Total: 449)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 68)
|
Target (Total: 28)
|
Buyer (Total: 17)
|
Target (Total: 6)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 96,461 | 42,000 |
| Revenue Per Employee | 457,425.3 | 425,978.0 |
| Total Revenue | 6,640.0 | 5,102.0 |
| Total Expenses | 4,603.0 | 4,174.0 |
Other Revenue
|
n/a | n/a |
|
Cost of Revenue
|
1,790.0 | 2,493.0 |
|
SG&A Expense
|
2,071.0 | 1,228.0 |
|
Research & Development
|
892.0 | 292.0 |
|
Other Operating Expense
|
-308.0 | n/a |
|
Operating Income
|
2,037.0 | 928.0 |
|
Unusual Income
|
133.0 | 149.0 |
|
LT Debt to Capital
|
57.74 | 30.59 |
|
Fwd P/E
|
11.28 | 6.95 |
|
Fwd P/Rev
|
2.50 | 1.71 |
| Book Value | 8,776.0 | 23,051.0 |
|
Curr Portion of LTD/Cap Lease
|
n/a | 531.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatalogicals and vaccines. The Company's segments include Pharmaceuticals and Consumer Healthcare. On July 22, 2009, it acquired Stiefel Laboratories, Inc. On October 30, 2009, it acquired Pfizer Inc.?s HIV business and combined it with its own HIV business to form ViiV Healthcare Limited. On November 10, 2009, it acquired the Algerian pharmaceutical, manufacturing and distribution group, Laboratoire Pharmaceutique Algerien. On December 18, 2009, it acquired NovaMin Technology Inc.
Target
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva?s active pharmaceutical ingredient (API) business provides vertical integration to Teva?s own pharmaceutical production. manufactures and sells generic pharmaceutical products in a range of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. During the year ended December 31, 2010, it acquired Laboratoire Theramex, Corporacion Infarmasa (Infarmasa) and Merckle ratiopharm Group (ratiopharm).
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
73.6 | 51.39 |
|
Operating Margin %
|
28.18 | 16.4 |
|
Quick Ratio
|
0.8 | 0.53 |
|
Current Ratio
|
1.12 | 1.1 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 40,802.0 | 50,470.0 |
| Return on Equity % | 273.46 | 50.6 |
| Return on Assets % | 58.82 | 23.11 |
|
Cash+ ST Inv. Per Share
|
1.16 | 1.25 |
| Total Debt | 14,715.0 | 14,522.0 |
| Total Debt to Equity % | 167.67 | 63 |
| Total Debt to Tangible Equity % | n/a | n/a |
|
Debt to Asset %
|
36.06 | 28.77 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
Consumer Products and Services |
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, sanitary/personal care paper (tissues), shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Buyer Products:
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
|
|
Scientific Products |
|
|
|
Bioanalytical Instruments
The Bioanalytical Subsector includes scientific products, devices, apparatuses, and consumables used to determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
Personal Care and Cleaning Products |
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Sanitary/Personal Care Paper
Companies engaged in the manufacturing of sanitary/personal care paper (tissues).
Buyer Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Adjunctive Treatments |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Anticholinergic Agents
Therapeutics that treat allergic reactions by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Target Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat acute coronary syndrome by due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the risk of chest pains by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat congestive heart failure by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the ineffective pumping of the heart by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Recombinant B-Type Natriuretic Peptides (BNP)
Therapeutics that treat the ineffective pumping of the heart by increasing the excretion of sodium and water in urine.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat the ineffective pumping of the heart by preventing the entry of sodium or potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat the ineffective pumping of the heart by acting on blood vessels to lower blood pressure.
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat/prevent myocardial infarction by blocking the angiotensin II receptor, which results in dilated blood vessels.
Target Products:
|
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors
Therapeutics that treat atherosclerosis by inhibiting lipoprotein-associated phospholipase A2 (Lp-PLA2), slowing the expansion of necrotic core, resulting in reduced buildup of arterial plaque.
Buyer Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Blockers/Beta Blockers
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the dopamine receptors of the heart muscle.
Target Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Target Products:
|
|
|
|
Hypotension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat low blood pressure by stimulating alpha adrenergic receptors.
Target Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Target Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.
Target Products:
|
|
|
|
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.
Buyer Products:
Target Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that reduce the risk of stroke by reducing high blood pressure through blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat damage to nerve cells of the brain by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Target Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Antibacterial Agents/Retinoids
Therapeutics that treat acne by preventing bacterial growth and helping in cell differentiation.
Buyer Products:
|
|
|
|
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.
Buyer Products:
|
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
Target Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat hair loss by dilating blood vessels.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Target Products:
|
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Immunomodulators
Therapeutics that treat atopic dermatitis by inhibiting T-lymphocyte activation.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Coal Tar
A coal byproducts used in the treatment of various skin disorders.
Buyer Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Buyer Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that treat psoriasis by providing vitamin D-like compounds.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Ulcer Adhering Agents
Therapeutics that treat peptic ulcers by binding to it and protecting it from further damage.
Target Products:
|
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Target Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat Esophagitis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Target Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Target Products:
|
|
|
|
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
Target Products:
|
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Target Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Target Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
CCR-9 Antagonists
Therapeutics that treat Crohn's Disease by blocking expression of chemokine receptors responsible for GI tract inflammation.
Buyer Products:
|
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation associated with ulcerative colitis by preventing the accumulation of inflammatory cells like leukocytes and macrophages to the inflammation site.
Target Products:
|
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Target Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Toothaches |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat toothache by numbing a localized area.
Target Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.
Buyer Products:
Target Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Target Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat hypertension by regulating the blood vessel dilation.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes |
|
|
|
Immunomodulators
Therapeutics that treat Insulin Dependent Diabetes Mellitus by modulating the immune response that causes the destruction of insulin producing beta cells.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat Insulin Dependent Diabetes Mellitus by modulating of immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Target Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Target Products:
|
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Buyer Products:
Target Products:
|
|
|
|
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Therapeutics that treat non-insulin dependent diabetes by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)/PPAR Agonists
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin and sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Dexamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Carnitine Deficiency |
|
|
|
Fatty Acid Transporters
Therapeutics that treat the depletion of long-chain fatty acids in the mitochondrial matrix by increasing carnitine level in the plasma, which facilitate the entry of long-chain fatty acids into the mitochondria.
Target Products:
|
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce cholesterol levels by reducing the levels of low-density lipoproteins (LDL) and increasing levels of high-density lipoproteins (HDL).
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increasing levels of high-density lipoproteins.
Target Products:
|
|
|
|
Lysosomal Storage Diseases |
|
|
|
Fabry Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Fabry's Disease by providing the missing enzymes that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.
Target Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Somatostatin Analogs
Therapeutics that prevents the secretion of growth hormones.
Target Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Target Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Target Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Target Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercalcemia |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat a disorder characterized by excessive calcium levels by inhibiting the resorption of bone.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increasing
levels of high-density lipoproteins.
Target Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that bind blood phosphorous.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Target Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Target Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Target Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Target Products:
|
|
|
|
Thrombocytopenia |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of white blood cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
CCR-9 Antagonists
Therapeutics that treat Crohn's Disease by blocking expression of chemokine receptors responsible for GI tract inflammation.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Discoid (DLE) |
|
|
|
Immunosuppressants
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques by inhibiting a full immune response.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques using a steroidal compound.
Target Products:
|
|
|
|
Systemic (SLE) |
|
|
|
Anti-dsDNA Inhibitors
Therapeutics that treat systemic lupus by selectively reducing antibodies to double-stranded DNA (dsDNA).
Target Products:
|
|
|
|
Hormonal
Therapeutics that treat systemic lupus with hormones.
Buyer Products:
|
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Target Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin by inhibiting the proliferation of skin cells.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
Target Products:
|
|
|
|
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Severe Combined Immunodeficiency Disease (Bubble Boy Disease) |
|
|
|
Enzymatic Agents
Therapeutics that treat a rare inherited disorder characterized by impairment or absence of the immune system at birth by replacing enzymes essential for normal immune system development.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Target Products:
|
|
|
|
Oxazolidinones
Therapeutics that treat a wide variety of infections by inhibiting early initiation of bacterial protein synthesis.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Target Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
Target Products:
|
|
|
|
Pleuromutilins
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis through binding onto ribosome.
Buyer Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Buyer Products:
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gingivitis |
|
|
|
Chlorhexidines
Therapeutics that treat inflammation of the gums by causing leakage in bacterial cell walls.
Target Products:
|
|
|
|
Periodontitis |
|
|
|
Tetracyclines
Therapeutics that treat bacterial infections of the gums, teeth, and underlying bone by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Neurology |
|
|
|
Meningitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Conjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the clear membrane outside the eye preventing the mast cell release of histamine.
Target Products:
|
|
|
|
Keratitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea caused by bacterial infection by inhibiting the release of histamine and leukotrienes from mast cells.
Target Products:
|
|
|
|
Keratoconjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea and the clear membrane outside the eye caused by bacterial infection by blocking the release of histamines from mast cells.
Target Products:
|
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Pneumonia |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Buyer Products:
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Target Products:
|
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Target Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Ascariasis (Roundworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.
Target Products:
|
|
|
|
Enterobiasis (Pinworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm. itching.
Target Products:
|
|
|
|
Hookworms |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the intestines.
Target Products:
|
|
|
|
Hydatid Disease |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by formation of cysts in a several organs.
Buyer Products:
|
|
|
|
Neurocysticercosis |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections caused by a tapeworm in the brain.
Buyer Products:
|
|
|
|
Trichuriasis (Whipworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by large worms attached to the lining of the large intestine.
Target Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Target Products:
|
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the nail by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Tinea Barbae |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Capitis |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Unquium |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pharynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Protozoan Metabolism Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by preventing metabolism and growth in organism.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Toxoplasmosis (Toxo) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections caused by Toxoplasma gondii and characterized by lesions in the heart, brain, and eye by preventing folic acid synthesis.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Malaria
Therapeutics that prevent or treat malaria infections, which are caused by protozoans of the genus Plasmodium.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.
Buyer Products:
Target Products:
|
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Viral Fusion Inhibitors
Therapeutics that treat cold sores by inhibiting fusion of viral material into human cell plasma membranes.
Buyer Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Influenza B |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
Target Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
Target Products:
|
|
|
|
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Combination |
|
|
|
Hepatitis A/Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to Hepatitis A and Hepatitis B viruses.
Buyer Products:
|
|
|
|
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Adenoviruses
Therapeutics that prevent or treat viral infections which commonly cause upper respiratory infections, such as common cold.
Target Products:
|
|
|
|
Hepatitis A
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis A virus.
Buyer Products:
|
|
|
|
Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis B virus.
Buyer Products:
|
|
|
|
Herpes Simplex
Therapeutics that prevent or treat viral infections characterized by vesicular eruption by producing or artificially increasing immunity to the Herpes Simplex virus.
Buyer Products:
|
|
|
|
Herpes Zoster (Shingles)
Therapeutics that prevent or treat viral infections that cause shingles in adults.
Buyer Products:
|
|
|
|
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.
Buyer Products:
|
|
|
|
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.
Buyer Products:
|
|
|
|
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.
Buyer Products:
|
|
|
|
Rotavirus
Therapeutics that prevent or treat viral infections that cause severe dehydrating diarrhea in children by producing or artificially increasing immunity to the rotavirus.
Buyer Products:
|
|
|
|
Varicella-Zoster Virus (Chicken Pox)
Therapeutics that prevent or treat viral infections that cause a blistery red rash by producing or artificially increasing immunity to the Varicella Zoster virus.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
Target Products:
|
|
|
|
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat osteoporosis by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Target Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Target Products:
|
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Target Products:
|
|
|
|
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
Therapeutics that treat the disorders involving the progressive degeneration and death of brain cells by preventing the actions of an amino acid neurotransmitter, N-Methyl-D-Aspartate.
Target Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat Alzheimer's Disease by stimulating immune response and regulating inflammation.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Target Products:
|
|
|
|
Potassium Channel Modulators/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid and opening of potassium channels.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Target Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Target Products:
|
|
|
|
Potassium Channel Modulators/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid and opening of potassium channels.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of sodium into nerve cells.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Grand Mal Seizures by preventing the entrance of sodium into nerve cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Target Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Target Products:
|
|
|
|
Headaches |
|
|
|
Chronic |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Cluster |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat Cluster Headaches by blocking the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Tension Type |
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists
Therapeutics that treat vascular headaches by inhibiting the action of cyclooxygenase, which is an inflammatory substance, as well as stimulating the serotonin receptor.
Buyer Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular headaches by attaching to specific receptors and mimicking the action of serotonin.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that prevent migraines by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation, as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Target Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Target Products:
|
|
|
|
Trigeminal Neuralgia (Tic Douloureux) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat trigeminal Neuralgia by inhibiting the entrance of sodium into the nerve cells.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Target Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by preventing the degradation of neurotransmitters.
Target Products:
|
|
|
|
Restless Leg Syndrome |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat Restless Leg Syndrome by stimulating dopamine activity.
Buyer Products:
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat restless legs syndrome by inhibiting the reuptake of GABA.
Buyer Products:
|
|
|
|
Tourette`s Syndrome |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the disorder involving uncontrolled verbal outbursts, ticks and facial expressions by blocking dopamine receptors on the neurons.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat obsessive compulsive disorder by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat panic disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD) by stimulating the adrenergic receptors, which cause nervous system stimulation.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Target Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Buyer Products:
Target Products:
|
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Target Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat bipolar disorders by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat bipolar disorders by blocking the sodium channels which in turn prevents the conductance of nerve impulses.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat depression by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat depression by inhibiting the activity of monoamine oxidase, which degrades neurotransmitters.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists/Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin as well as blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Sleep Disorders |
|
|
|
Excessive Daytime Sleepiness (EDS) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat excessive daytime sleepiness (EDS) by stimulating the adrenergic receptors, which cause nervous system stimulation.
Target Products:
|
|
|
|
Insomnia |
|
|
|
Antihistamines
Therapeutics that treat insomnia by preventing the functions of histamine on tissues.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
Target Products:
|
|
|
|
Orexin Receptor Antagonists
Therapeutics that treat insomnia by inhibiting the action of orexin.
Buyer Products:
|
|
|
|
Narcolepsy |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.
Target Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving chronic and sudden daytime sleepiness.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Induction/Cervical Ripening |
|
|
|
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.
Target Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometrial Hyperplasia |
|
|
|
Progestins
Therapeutics that treat a disorder involving the benign proliferation of cells lining the uterus (endometrium) by increasing progesterone levels in the body.
Target Products:
|
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Target Products:
|
|
|
|
Progestins
Therapeutics that treat female disorders characterized by the inability to achieve pregnancy or carry a pregnancy to term by increasing progesterone level in the body to induce uteran conditions favorable to conception and pregnancy.
Target Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage breast cancers by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Target Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Estrogen Synthesis Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting the conversion of adrenal androgens to estrogen in peripheral tissues.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat breast cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Malignant Melanoma |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Malignant Melanoma by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Target Products:
|
|
|
|
Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (MEK) Inhibitors
Therapeutics that stop the growth of cancer cells by blocking some of the enzymes necessary for cancer cell growth.
Buyer Products:
|
|
|
|
Raf Kinase Inhibitors
Therapeutics that treat skin cancer by interrupting the signaling pathways that are responsible for tumor cell proliferation.
Buyer Products:
|
|
|
|
Reactive Oxygen Species (ROS) Inducers
Therapeutics that treat skin cancer by inducing oxidative stress inside tumor cells and triggering programmed cell death.
Buyer Products:
|
|
|
|
Vaccines
Therapeutics that are meant to promote an immune response against a patient's melanoma.
Buyer Products:
|
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancers of keratinizing epidermal cells by interacting with DNA.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage colorectal cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Target Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat gastric cancer by inhibiting the action of tyrosine kinase, compounds that play a vital role in cell division.
Buyer Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage primary tumors of the pancreas by inhibiting the production of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage pancreatic cancers by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage pancreatic cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage metastatic pancreatic cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Endocrinology |
|
|
|
Carcinoid Tumors |
|
|
|
Palliative Agents |
|
|
|
Somatostatin Analogs
Therapeutics that treat and manage a serotonin secreting neoplasm known as a carcinoid tumor by inhibiting the secretion of growth hormone which allows the tumor to grow rapidly.
Target Products:
|
|
|
|
Parathyroid Gland |
|
|
|
Palliative Agents |
|
|
|
Calcimimetic Agents
Therapeutics that treat hypercalcemia (elevated calcium levels in the blood) by decreasing parathyroid hormone levels.
Target Products:
|
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the head and neck by interacting with DNA.
Target Products:
|
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
Target Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Lymphocytic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics isolated principally from microorganisms that treat rapidly progressing cancers of lymphocytic cells by interacting with DNA.
Target Products:
|
|
|
|
Chronic |
|
|
|
Lymphocytic (CLL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Erythroleukemic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Monocytic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cellsby interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.
Target Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage rapidly progressing cancers of myelogenous cells by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Promyelocytic (APL) |
|
|
|
DNA Fragmenting Agents
Therapeutics that treat leukemia by breaking DNA, resulting in the death of cancer cells.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Chronic |
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of immature myeloid cells by inhibiting the production of DNA.
Target Products:
|
|
|
|
Myelogenous (CML) |
|
|
|
Mcl-1 Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by inhibiting Mcl-1 protein synthesis, leading to cancer cell death (apoptosis).
Target Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Alkylsulfonates
Therapeutics that treat and manage cancers of myeliod cells by cross-linking and breaking DNA strands which ultimately leads to cell death.
Buyer Products:
|
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of myeliod cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Hodgkin's Disease by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Target Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division but that are not curative.
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage lymphomas of B-cells and T-cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphomas of B-cells and T-cells by interacting with DNA.
Target Products:
|
|
|
|
Radioactive Agents/Monoclonal Antibodies
Therapeutics that utilize a monoclonal antibody to target a local dose of radiation to lymphoma cells in order to induce their death.
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Target Products:
|
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mature antibody producing white blood cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Osteolytic Bone Metastases |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.
Target Products:
|
|
|
|
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat cancer bone metastases by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.
Buyer Products:
|
|
|
|
Rhabdomyosarcoma |
|
|
|
Angiogenesis Inhibitors
Therapeutics that treat rhabdomyosarcomas by inhibiting the growth of blood vessels around malignant growths, effectively cutting off the blood/nutrient supply.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Neuroblastoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Angiogenesis Inhibitors
Therapeutics that inhibit the growth of blood vessels around cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, effectively cutting off the blood/nutrient supply.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
Target Products:
|
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by inhibiting the production of DNA.
Target Products:
|
|
|
|
Vaccines
Therapeutics that are meant to promote an immune response against a patient's non-small cell lung cancer (NSCLC).
Buyer Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase I, which is needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary malignant tumors of the cervix by interacting with DNA.
Target Products:
|
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the cervix by inhibiting a specific enzyme, topoisomerase I, which is needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Localized |
|
|
|
Angiogenesis Inhibitors
Therapeutics that treat localized renal cell carcinomas by inhibiting the growth of blood vessels around malignant growths, effectively cutting off the blood/nutrient supply.
Buyer Products:
|
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
Target Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Germ Cell Tumors |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by inhibiting a specific enzyme, topoisomerase I, needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Target Products:
|
|
|
|
Penile Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the squamous cells of the penis by interacting with DNA.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that treat prostate cancer by inhibiting the formation of Dihydrotestosterone from testosterone.
Buyer Products:
|
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Target Products:
|
|
|
|
Antisense Agents
Therapeutics that treat metastatic prostate cancer by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.
Target Products:
|
|
|
|
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat cancer bone metastases by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations but are not curative.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.
Target Products:
|
|
|
|
Testicular Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage primary tumors of the testes by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the testes by interacting with DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage testicular cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage mushroom shaped tumors that arise from the inner lining of the bladder by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Transitional Cell Carcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancers arising from the lining of the bladder by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers that arise from skin cells of the external female genitalia by interacting with DNA.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Glaucoma |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Target Products:
|
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Target Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Target Products:
|
|
|
|
Primary |
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Target Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Target Products:
|
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially, as well as prevent inflammation by inhibiting the action of prostaglandins.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that dilate the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine, and counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Muscarinic Receptor Antagonists
Therapeutics that cause dilation of the lung passages through dual action of supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine, and by blocking the action of choline and other cholinergic agents by binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that dilate the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine, and counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Anticholinergic Agents
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine and by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Target Products:
|
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat the by blocking the action of choline and other cholinergic agents by binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that are used to prevent COPD attacks by preventing inflammation and stimulating beta adrenergic receptors.
Buyer Products:
|
|
|
|
Emphysema |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Target Products:
|
|
|
|
Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
Target Products:
|
|
|
|
Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and relieving pain and fever.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
Target Products:
|
|
|
|
Nasal Dryness |
|
|
|
Moisturizing Agents
Therapeutics that treat nasal dryness by providing moisture to the nasal passages.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Ischemia |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Post-Operative Ileus/Constipation |
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent post surgical nausea and vomiting through a combination of blocking neurotransmitters and gastrointestinal movement stimulants.
Target Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
Target Products:
|
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of surgical complications in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Chemical Poisoning |
|
|
|
Digoxin |
|
|
|
Digoxin Binding Agents
Therapeutics that treat toxicity due to ingestion of excessive digoxin by competitively binding to digoxin, making them unavailable for binding at their site of action on cells in the body.
Buyer Products:
|
|
|
|
Heavy Metal Poisoning |
|
|
|
Chelating Agents |
|
|
|
Iron
Therapeutics that form chemical complexes with iron and are subsequently excreted.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of toxicity in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Opioid Analgesics
Therapeutics that treat narcotic withdrawal by providing the body with a milder opioid substitute.
Target Products:
|
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotine Conjugate Vaccine
Therapeutics that treat nicotine withdrawal by stimulating the immune system to produce antibodies that bind to nicotine, and preventing it from crossing the blood-brain barrier.
Buyer Products:
|
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that increase the concentration of several neurotransmitters in the brain by inhibiting their uptake.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Bone Marrow |
|
|
|
Complications |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cells called granulocytes.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the breakdown of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Target Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
Target Products:
|
|
|
|
5-Alpha Reductase Inhibitors/Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT)--a substance that causes enlargement of the prostate, and also causes the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Target Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat puberty disorders by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Cystitis |
|
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Target Products:
|
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat COPD by blocking the action of choline and other cholinergic agents from binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Hyperparathyroidism |
|
|
|
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.
Target Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.
Target Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that treat abnormal levels of phosphate in the blood by binding to excess phosphate groups.
Target Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat diabetes induced kidney diseases by inhibiting a certain enzyme necessary for regulation of blood pressure.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Anorexia (Appetite Loss) |
|
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Target Products:
|
|
|
|
Cachexia |
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Target Products:
|
|
|
|
Obesity |
|
|
|
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.
Buyer Products:
|
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Burns |
|
|
|
Maintenance |
|
|
|
Tissue (Skin) Removal |
|
|
|
Debriding Agents
Therapeutics that treat skin injuries caused by fire or excessive heat by removing dead skin from the wound by catalyzing the breakdown of collagen.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Microbiology Identification |
|
|
|
Bacterial
Test kits used to identify bacterial organisms in a culture source. Biochemical presumptive identification test kits are included, as well as kits for testing bacterial sensitivity to antibiotics.
Buyer Products:
|
|
|
|
Immunoassays |
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Allergy
Immunassay kits used to detect and quantitate allergy associated analytes.
Buyer Products:
|
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Dry Powder |
|
|
|
Inhalers (DPI)
Mouthpiece-type of medical devices from which the patients inhale the medication mixture
Buyer Products:
|
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Buyer Products:
|
|
|
|
Manual
Inhalation devices which are activated by the patient's manual control
Buyer Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Target Products:
|
|
|
|
Respiratory |
|
|
|
Treatment |
|
|
|
Nasal Expanders
Device designed to expand the nasal passages.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Biopharmaceutical OEM |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
Target Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Target Products:
|
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Molecular Complex
Drug Delivery Technologies used to deliver drugs using a substance with the drugs embedded in it.
Target Products:
|
|
|
|
Transmucosal |
|
|
|
Drug Matrix
Drug Delivery Technologies used to deliver drugs using a substance with the drugs embedded in it.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Bioanalytical Instruments |
|
|
|
Bioanalytical Consumables |
|
|
|
Cell Biology |
|
|
|
Cell Culture |
|
|
|
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Merck & Co Inc
|
|
n/a | 116,518.823 | 16.80 | 9.96 | 2.42 | 2.49 | 12.01 | |
|
Amgen Inc
|
|
n/a | 63,900.920 | 17.21 | 11.66 | 4.01 | 3.99 | 19.32 | |
|
Astrazeneca PLC
|
|
n/a | 55,862.085 | 6.70 | 6.82 | 1.71 | 1.94 | 90.39 | |
|
Gilead Sciences Inc
|
|
n/a | 38,526.468 | 14.94 | 14.61 | 4.41 | 4.22 | n/a | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Allergan Inc
|
|
n/a | 27,300.906 | 27.16 | 21.26 | 4.93 | 4.66 | 12.31 | |
|
Dr Reddy'S Laboratories Ltd
|
|
n/a | 5,067.326 | 0.43 | 17.13 | 0.07 | n/a | 0.12 | |
|
Salix Pharmaceuticals Ltd
|
|
n/a | 2,896.808 | 29.50 | 20.09 | 4.78 | 3.93 | 6.09 | |
|
United Therapeutics Corp
|
|
n/a | 2,428.303 | 9.58 | 9.37 | 3.09 | 2.82 | 2.40 | |
|
Ariad Pharmaceuticals Inc
|
|
n/a | 2,118.104 | n/a | -12.64 | 83.65 | 186.35 | 8.23 | |
|
Taro Pharmaceutical Industries Ltd
|
|
n/a | 1,771.145 | 9.70 | n/a | 3.50 | n/a | 3.12 | |
|
Akorn Inc
|
|
n/a | 1,225.611 | 26.11 | 26.29 | 7.51 | 4.66 | 29.45 | |
|
Momenta Pharmaceuticals Inc
|
|
n/a | 707.734 | 6.08 | -18.63 | 3.09 | 9.01 | n/a | |
|
Spectrum Pharmaceuticals Inc
|
|
n/a | 589.433 | 6.90 | 7.47 | 2.82 | 2.58 | 2.96 | |
|
Emergent BioSolutions Inc
|
|
n/a | 498.683 | 22.51 | 22.48 | 1.82 | 1.77 | 1.40 | |
|
CytRx Corp
|
|
n/a | 447.174 | n/a | n/a | 1,772.21 | n/a | 31.37 | |
|
Arqule Inc
|
|
n/a | 310.543 | n/a | -19.38 | 7.32 | 7.88 | 11.26 | |
|
Antares Pharma Inc
|
|
n/a | 299.459 | n/a | -98.00 | 15.16 | 11.98 | 9.97 | |
|
Depomed Inc
|
|
n/a | 283.458 | n/a | -7.26 | 4.25 | 3.84 | 2.86 | |
|
Xenoport Inc
|
|
n/a | 206.615 | n/a | -3.79 | 3.86 | 9.39 | 3.00 | |
| Buyer | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Procter & Gamble Co
|
|
n/a | 174,538.223 | 13.86 | 16.57 | 1.64 | 2.08 | n/a | |
| Target | |||||||||
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Merck & Co Inc
|
|
n/a | 116,518.823 | 16.80 | 9.96 | 2.42 | 2.49 | 12.01 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Shire PLC
|
|
n/a | 16,927.268 | 9.59 | 14.88 | 3.97 | 3.58 | 170.29 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,667.459 | n/a | -9.30 | 17.60 | 11.94 | 7.08 | |
|
Codexis Inc
|
|
n/a | 112.024 | n/a | -5.42 | 0.90 | 0.89 | 1.45 | |
|
Skyepharma PLC
|
|
n/a | 28.492 | n/a | n/a | 0.34 | n/a | n/a | |
|
Gerresheimer AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Celldex Therapeutics Inc
|
|
98.00% | 181.445 | n/a | -4.27 | 19.77 | 21.11 | 2.44 | |
|
Anacor Pharmaceuticals Inc
|
|
53.00% | 149.677 | n/a | -3.17 | 7.30 | 8.98 | 7.24 | |
| Target | |||||||||
|
Antares Pharma Inc
|
|
44.00% | 299.459 | n/a | -98.00 | 15.16 | 11.98 | 9.97 | |
|
3M Co
|
|
n/a | 59,253.326 | 13.85 | 13.14 | 1.99 | 1.95 | 7.73 | |
|
Astrazeneca PLC
|
|
n/a | 55,862.085 | 6.70 | 6.82 | 1.71 | 1.94 | 90.39 | |
|
Shire PLC
|
|
n/a | 16,927.268 | 9.59 | 14.88 | 3.97 | 3.58 | 170.29 | |
|
Valeant Pharmaceuticals International Inc
|
|
n/a | 14,153.627 | 107.56 | 10.97 | 5.14 | 4.15 | n/a | |
|
Perrigo Co
|
|
n/a | 9,216.636 | 24.78 | 20.17 | 3.03 | 2.90 | 49.14 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,667.459 | n/a | -9.30 | 17.60 | 11.94 | 7.08 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
|
Impax Laboratories Inc
|
|
n/a | 1,378.523 | 21.35 | 11.71 | 2.59 | 2.16 | 2.50 | |
|
OncoGenex Pharmaceuticals Inc
|
|
n/a | 123.805 | n/a | -5.69 | 22.06 | 7.95 | 1.58 | |
|
Compugen Ltd
|
|
n/a | 123.460 | n/a | n/a | n/a | n/a | 6.31 | |
|
Codexis Inc
|
|
n/a | 112.024 | n/a | -5.42 | 0.90 | 0.89 | 1.45 | |
|
CEL-SCI Corp (New)
|
|
n/a | 82.974 | n/a | n/a | 223.62 | n/a | 14.17 | |
|
Savient Pharmaceuticals Inc
|
|
n/a | 60.888 | n/a | -0.56 | 5.16 | 3.02 | n/a | |
|
Rexahn Pharmaceuticals Inc
|
|
n/a | 38.095 | n/a | n/a | 1,023.53 | n/a | 3.56 | |
|
Biosante Pharmaceuticals Inc
|
|
n/a | 37.380 | n/a | -1.39 | 76.55 | 50.78 | 0.98 | |
|
Skyepharma PLC
|
|
n/a | 28.492 | n/a | n/a | 0.34 | n/a | n/a | |
|
Autoimmune Inc
|
|
n/a | 0.039 | n/a | n/a | 0.06 | n/a | 0.00 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
| Buyer | |||||||||
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
|
Eli Lilly & Co
|
|
n/a | 46,816.943 | 10.86 | 12.39 | 1.95 | 2.07 | 4.89 | |
|
Celgene Corp
|
|
n/a | 31,244.689 | 21.68 | 15.88 | 6.26 | 5.82 | 5.14 | |
|
Allergan Inc
|
|
n/a | 27,300.906 | 27.16 | 21.26 | 4.93 | 4.66 | 12.31 | |
|
Warner Chilcott PLC
|
|
n/a | 5,056.104 | 16.51 | 5.90 | 1.90 | 2.08 | n/a | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
|
Pozen Inc
|
|
n/a | 194.151 | 4.94 | -7.93 | 2.32 | 19.72 | 1.98 | |
|
Farabi Pharmaceutical Co
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ahmed Mohammed Abdul Wahab Naghi & Sons Co.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Corporativo Fragua SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Adherex Technologies Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
GAVI Alliance
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Government - Brazil
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PROTEK OJSC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
World Health Organization (WHO)
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Watson Pharmaceuticals Inc
|
|
n/a | 9,376.965 | 34.60 | 12.22 | 1.79 | 1.71 | 385.88 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
|
Medicines Co
|
|
n/a | 1,127.778 | 5.02 | 19.57 | 1.32 | 2.12 | 2.90 | |
|
Paladin Labs Inc
|
|
n/a | 837.215 | 15.61 | n/a | 5.64 | n/a | 2.71 | |
|
Transcept Pharmaceuticals Inc
|
|
n/a | 94.523 | n/a | -5.86 | 5.71 | 10.32 | 1.60 | |
|
H. Lundbeck A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Shire PLC
|
|
n/a | 16,927.268 | 9.59 | 14.88 | 3.97 | 3.58 | 170.29 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,667.459 | n/a | -9.30 | 17.60 | 11.94 | 7.08 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
|
Impax Laboratories Inc
|
|
n/a | 1,378.523 | 21.35 | 11.71 | 2.59 | 2.16 | 2.50 | |
|
Medicines Co
|
|
n/a | 1,127.778 | 5.02 | 19.57 | 1.32 | 2.12 | 2.90 | |
|
Skyepharma PLC
|
|
n/a | 28.492 | n/a | n/a | 0.34 | n/a | n/a | |
|
Lonza Group AG
|
|
n/a | n/a | n/a | 6.50 | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
| Target | |||||||||
|
Procter & Gamble Co
|
|
n/a | 174,538.223 | 13.86 | 16.57 | 1.64 | 2.08 | n/a | |
|
Novo-Nordisk A/S (vormals Novo Industri A/S)
|
|
n/a | 66,851.111 | 10.69 | 22.48 | 1.64 | 4.95 | 1.86 | |
|
3M Co
|
|
n/a | 59,253.326 | 13.85 | 13.14 | 1.99 | 1.95 | 7.73 | |
|
Shire PLC
|
|
n/a | 16,927.268 | 9.59 | 14.88 | 3.97 | 3.58 | 170.29 | |
|
Watson Pharmaceuticals Inc
|
|
n/a | 9,376.965 | 34.60 | 12.22 | 1.79 | 1.71 | 385.88 | |
|
Perrigo Co
|
|
n/a | 9,216.636 | 24.78 | 20.17 | 3.03 | 2.90 | 49.14 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,667.459 | n/a | -9.30 | 17.60 | 11.94 | 7.08 | |
|
Myriad Genetics Inc
|
|
n/a | 2,087.998 | 26.06 | 19.08 | 4.44 | 4.27 | 3.60 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,425.793 | 26.90 | 10.14 | 1.48 | 1.33 | n/a | |
|
Impax Laboratories Inc
|
|
n/a | 1,378.523 | 21.35 | 11.71 | 2.59 | 2.16 | 2.50 | |
|
Medicines Co
|
|
n/a | 1,127.778 | 5.02 | 19.57 | 1.32 | 2.12 | 2.90 | |
|
Genomic Health Inc
|
|
n/a | 933.427 | 114.21 | n/a | 4.35 | 4.06 | 7.62 | |
|
Paladin Labs Inc
|
|
n/a | 837.215 | 15.61 | n/a | 5.64 | n/a | 2.71 | |
|
Protalix BioTherapeutics Inc
|
|
n/a | 530.623 | n/a | 86.86 | 764.82 | 17.46 | n/a | |
|
Antares Pharma Inc
|
|
n/a | 299.459 | n/a | -98.00 | 15.16 | 11.98 | 9.97 | |
|
Biotime Inc
|
|
n/a | 196.455 | n/a | n/a | 29.05 | n/a | 32.12 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 31,752.9 | 19,334.0 | 51,086.9 |
|
Other Revenue
|
n/a | n/a | n/a |
| Total Revenue | 31,752.9 | 19,334.0 | 51,086.9 |
|
Cost of Revenue
|
8,381.6 | 9,398.0 | 17,779.6 |
|
SG&A Expense
|
9,885.5 | 4,564.0 | 14,449.5 |
|
Depreciation & Amortization
|
25.0 | 33.0 | 58.0 |
|
Research & Development
|
4,511.6 | 1,133.0 | 5,644.6 |
|
Interest Expense
|
n/a | n/a | n/a |
|
Other Operating Expense
|
-640.8 | n/a | -640.8 |
|
Unusual Expense (Income)
|
642.3 | 1,036.0 | 1,678.3 |
| Total Expenses | 22,805.3 | 16,164.0 | 38,969.3 |
|
Operating Income
|
8,947.6 | 3,170.0 | 12,117.6 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-742.3 | -185.0 | -927.3 |
|
Gain/Loss On Sale Of Assets
|
1.0 | n/a | 1.0 |
|
Other, Net
|
n/a | n/a | n/a |
| Income Before Taxes | 8,134.3 | 2,985.0 | 11,119.3 |
| Income Taxes | 2,134.5 | 69.0 | 2,203.5 |
| Income After Taxes | 5,999.8 | 2,916.0 | 8,915.8 |
| Minority Interest (IS) | -229.3 | -1.0 | -230.3 |
| Equity in Affiliates | n/a | -58.0 | -58.0 |
|
Net Income - Excl. Xord. Items
|
5,770.5 | 2,857.0 | 8,627.5 |
|
Net Income - Incl. Xord. Items
|
5,770.5 | 2,857.0 | 8,627.5 |
|
Income Avail. to Common
|
5,770.5 | 2,857.0 | 8,627.5 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
4,963.0 | 880.0 | 5,843.0 |
|
Basic EPS - Excl. Xord. Items
|
1.15 | 3.23 | 1.48 |
|
Basic EPS - Incl. Xord. Items
|
1.51 | 3.23 | 1.48 |
| Full Dilution Adjustment | n/a | n/a | n/a |
| Fully Diluted Shares Outstanding | 5,035.0 | 882.0 | 5,917.0 |
|
F.D. EPS - Excl. Xord. Items
|
1.49 | 3.22 | 1.46 |
|
F.D. EPS - Incl. Xord. Items
|
1.49 | 3.22 | 1.46 |
| Dividends Per Common Share | 1.13 | 0.98 | 2.11 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
5,636.0 | 1,062.0 | 6,698.0 |
|
ST Investments
|
203.0 | 38.0 | 241.0 |
|
Accounts Receivable
|
5,840.0 | 6,056.0 | 11,896.0 |
|
Inventory
|
4,008.0 | 5,332.0 | 9,340.0 |
|
Other Current Assets
|
591.0 | 2,517.0 | 3,108.0 |
|
Current Assets
|
16,278.0 | 14,967.0 | 31,245.0 |
|
Accum D&A
|
n/a | n/a | n/a |
|
PPE, Net
|
8,616.0 | 6,083.0 | 14,699.0 |
| Goodwill & Intangibles | 11,264.0 | 28,213.0 | 39,477.0 |
| Long Term Investments | 1,199.0 | 1,044.0 | 2,243.0 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
3,445.0 | 163.0 | 3,608.0 |
| Total Assets | 40,802.0 | 50,470.0 | 91,272.0 |
| Liabilities | |||
| Accounts Payable | 7,058.0 | n/a | 7,058.0 |
| Payable/Accrued | n/a | 3,199.0 | 3,199.0 |
|
ST Debt
|
2,723.0 | 3,834.0 | 6,557.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
n/a | 531.0 | 531.0 |
| Other (Current) Liabilities | 4,752.0 | 6,063.0 | 10,815.0 |
|
Current Liab.
|
14,533.0 | 13,627.0 | 28,160.0 |
|
LT Debt
|
11,992.0 | 10,157.0 | 22,149.0 |
|
Total LT Debt
|
11,992.0 | 10,157.0 | 22,149.0 |
| Minority Interest (BS) | 800.0 | 149.0 | 949.0 |
| Deferred Taxes | 824.0 | 2,210.0 | 3,034.0 |
|
Other LT Liab.
|
3,877.0 | 1,276.0 | 5,153.0 |
|
Total Liabilities
|
32,026.0 | 27,419.0 | 59,445.0 |
| Shareholders Equity | |||
| Common Stock | 1,390.0 | n/a | 1,390.0 |
| Additional Paid in Capital | 1,782.0 | n/a | 1,782.0 |
| Retained Earnings | 5,604.0 | n/a | 5,604.0 |
| Other Equity | n/a | 23,051.0 | 23,051.0 |
|
Total Equity
|
8,776.0 | 23,051.0 | 31,827.0 |
|
Total Liab. & Equity
|
40,802.0 | 50,470.0 | 91,272.0 |
|
Shares Outstanding
|
4,962.0 | 942.0 | 5,904.0 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 5,999.8 | 2,858.0 | 8,857.8 |
| CF Depreciation | 2,085.3 | -1,227.0 | 858.3 |
| CF Deferred Taxes | n/a | 396.0 | 396.0 |
| Other Non-Cash Items | 2,949.8 | 1,624.0 | 4,573.8 |
| Change in Working Capital | -3,933.0 | 339.0 | -3,594.0 |
| Total Cash From Operating Activities | 7,101.9 | 3,990.0 | 11,091.9 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,510.9 | 1,196.0 | -314.9 |
| Other Investing Cash Flows | 531.0 | -8,315.0 | -7,784.0 |
| Total Cash From Investing Activities | -979.9 | -7,119.0 | -8,098.9 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -4,157.3 | 1,016.0 | -3,141.3 |
| Purchase Or Sale of Stock | -1,996.7 | 1,158.0 | -838.7 |
| Purchase and Retirement of Debt | 1.9 | -32.0 | -30.1 |
| Other Financing Cash Flow | -1,138.9 | 1,351.0 | 212.1 |
| Total Cash From Financing Activities | -7,291.0 | 3,493.0 | -3,798.0 |
| Exchange Rate Effects | -91.8 | -23.0 | -114.8 |
| Net Change in Cash | -1,260.9 | 341.0 | -919.9 |
| Cash Taxes Paid | -1,095.5 | n/a | -1,095.5 |
| Cash Interest Paid | -271.6 | n/a | -271.6 |